PRTN3 and fatty liver disease: Notably, therapeutic interventions with Respreeza, a human serum-derived form of A1AT, and sivelestat, a PR3 inhibitor, significantly reduced the MoKC proportion, liver steatosis, inflammation and fibrosis in mice.